News Cidara Therapeutics, Inc.

Equities

CDTX

US1717571079

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-16 pm EDT			5-day change	1st Jan Change
0.73 ^USD	-11.48%		-16.57%	-8.06%

Apr. 11	North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge	DJ
Apr. 04	North American Morning Briefing : Focus Turns to -2-	DJ

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge	Apr. 11	DJ
Cidara Therapeutics Presents Promising New Data on Novel Drug-Fc Conjugate Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2024	Apr. 05	AQ
North American Morning Briefing : Focus Turns to -2-	Apr. 04	DJ
North American Morning Briefing : Stocks Set for -2-	Mar. 28	DJ
CIDARA THERAPEUTICS TO PRESENT PRECLINCAL DATA ON MULTIPLE NOVEL DRUG-FC CONJUGATE CANDIDATES AT AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING 2024	Mar. 07	AQ
Cidara Therapeutics to Present Preclincal Data on Multiple Novel Drug-Fc Conjugate Candidates at American Association dor Cancer Research (AACR) Annual Meeting 2024	Mar. 06	AQ
Cidara Therapeutics Receives $11.14 Million Milestone Payment Following European Approval of REZZAYO	Feb. 12	AQ
North American Morning Briefing : Microsoft Kicks Off Big Tech Bonanza	Jan. 30	DJ
Cidara Therapeutics Says UK Regulator Approved Invasive Candidiasis Treatment	Jan. 30	MT
Cidara Therapeutics Announces Approval of REZZAYO by the MHRA for the Treatment of Invasive Candidiasis in Adults	Jan. 29	AQ
Cidara Therapeutics, Inc. Announces Approval of REZZAYO by the MHRA for the Treatment of Invasive Candidiasis in Adults	Jan. 29	CI
Cidara Therapeutics Announces European Approval of REZZAYO® (rezafungin) for the Treatment of Invasive Candidiasis in Adults	Dec. 22	AQ
Cidara Therapeutics Presents New Promising Preclincal Data on Novel Dual-Acting Drug-Fc Conjugates at ESMO Immuno-Oncology Annual Congress	Dec. 07	AQ
Melinta Therapeutics and Cidara Therapeutics Announce Publication of Pooled Data from Phase 3 Pivotal ReSTORE trial and Phase 2 STRIVE Trial of REZZAYO for the Treatment of Candidemia	Dec. 06	AQ
Cidara Therapeutics Announces Completion of Enrollment in Phase 3 Restore Trial of Rezafungin in China	Dec. 06	AQ
Cidara Therapeutics Announces Completion of Enrollment in Phase 3 Restore Trial of Rezafungin in China	Dec. 06	CI
Melinta Therapeutics, Llc and Cidara Therapeutics, Inc. Announce Publication of Pooled Data from Phase 3 Pivotal Restore Trial & Phase 2 Strategic Trial of Rezafungin for Injection in the Lancet Id	Dec. 05	CI
Cidara Therapeutics to Present New Preclinical Data on Novel Dual-Acting Drug-Fc Conjugates at ESMO Immuno-Oncology Annual Congress	Nov. 30	AQ
Cidara Therapeutics Named as a San Diego Metro Area Top Workplace	Nov. 20	AQ
Cidara Therapeutics Presents Preclinical Data on Novel Drug-Fc Conjugate CBO421 at SITC’s 38ᵗʰ Annual Meeting	Nov. 03	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Cidara Therapeutics, Inc.

Equities

CDTX

US1717571079

Summary

Filters